Literature DB >> 18813840

ERK2 CD domain mutation from a human cancer cell line enhanced anchorage-independent cell growth and abnormality in Drosophila.

Marthandan Mahalingam1, Ramanathan Arvind, Hiroyuki Ida, Avaniyapuram Kannan Murugan, Masamitsu Yamaguchi, Nobuo Tsuchida.   

Abstract

In a human cancer cell line, we previously found a mutation in codon 322 of the extracellular signal-regulated kinase (ERK2E322K), the protein showed a faster migration when compared to wild-type in SDS-PAGE and constitutive phosphorylation. However, the reason for the faster migration, and the biochemical and biological properties of the mutation is unknown. In this study, we report that the amino acid charge-change mutation in the common docking (CD) domain is important for fast migration. In vitro binding of ERK2E322K to MKP1 and RSK2 was lost, resulting in constitutive activation and possibly contributing to a more efficient colony formation in soft agar. We established transgenic flies by carrying the corresponding CD domain mutation, DERKE335K, which developed smaller and rougher eyes compared with the wild-type. Taken together, these data are consistent with ERK2E322K loss of contact with downstream effectors and its constitutive activation, presenting an oncogenic potential and weak abnormality in differentiation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18813840

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  7 in total

1.  Genomic Correlate of Exceptional Erlotinib Response in Head and Neck Squamous Cell Carcinoma.

Authors:  Eliezer M Van Allen; Vivian W Y Lui; Ann Marie Egloff; Eva M Goetz; Hua Li; Jonas T Johnson; Umamaheswar Duvvuri; Julie E Bauman; Nicolas Stransky; Yan Zeng; Breean R Gilbert; Kelsey P Pendleton; Lin Wang; Simion Chiosea; Carrie Sougnez; Nikhil Wagle; Fan Zhang; Yu Du; David Close; Paul A Johnston; Aaron McKenna; Scott L Carter; Todd R Golub; Gad Getz; Gordon B Mills; Levi A Garraway; Jennifer R Grandis
Journal:  JAMA Oncol       Date:  2015-05       Impact factor: 31.777

2.  Functional divergence caused by mutations in an energetic hotspot in ERK2.

Authors:  Clinton A Taylor; Kevin W Cormier; Shannon E Keenan; Svetlana Earnest; Steve Stippec; Chonlarat Wichaidit; Yu-Chi Juang; Junmei Wang; Stanislav Y Shvartsman; Elizabeth J Goldsmith; Melanie H Cobb
Journal:  Proc Natl Acad Sci U S A       Date:  2019-07-11       Impact factor: 11.205

Review 3.  Targeting mitochondrial metabolism for metastatic cancer therapy.

Authors:  Antonino Passaniti; Myoung Sook Kim; Brian M Polster; Paul Shapiro
Journal:  Mol Carcinog       Date:  2022-06-20       Impact factor: 5.139

Review 4.  Mutations That Confer Drug-Resistance, Oncogenicity and Intrinsic Activity on the ERK MAP Kinases-Current State of the Art.

Authors:  Karina Smorodinsky-Atias; Nadine Soudah; David Engelberg
Journal:  Cells       Date:  2020-01-06       Impact factor: 6.600

5.  MAPK1E322K mutation increases head and neck squamous cell carcinoma sensitivity to erlotinib through enhanced secretion of amphiregulin.

Authors:  Yihui Wen; Hua Li; Yan Zeng; Weiping Wen; Kelsey P Pendleton; Vivian W Y Lui; Ann Marie Egloff; Jennifer R Grandis
Journal:  Oncotarget       Date:  2016-04-26

6.  Activating MAPK1 (ERK2) mutation in an aggressive case of disseminated juvenile xanthogranuloma.

Authors:  Rikhia Chakraborty; Oliver A Hampton; Harshal Abhyankar; Daniel J Zinn; Amanda Grimes; Brooks Skull; Olive Eckstein; Nadia Mahmood; David A Wheeler; Dolores Lopez-Terrada; Tricia L Peters; John M Hicks; Tarek Elghetany; Robert Krance; Poulikos I Poulikakos; Miriam Merad; Kenneth L McClain; Carl E Allen; Donald W Parsons
Journal:  Oncotarget       Date:  2017-07-11

7.  Mechanistic Analysis of an Extracellular Signal-Regulated Kinase 2-Interacting Compound that Inhibits Mutant BRAF-Expressing Melanoma Cells by Inducing Oxidative Stress.

Authors:  Ramon Martinez; Weiliang Huang; Ramin Samadani; Bryan Mackowiak; Garrick Centola; Lijia Chen; Ivie L Conlon; Kellie Hom; Maureen A Kane; Steven Fletcher; Paul Shapiro
Journal:  J Pharmacol Exp Ther       Date:  2020-10-27       Impact factor: 4.030

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.